RTI Surgical, Inc. Purchases Zyga Technology
Elizabeth Hofheinz, M.P.H., M.Ed. • Wed, January 24th, 2018
Alachua, Florida-based RTI Surgical, Inc. has purchased Minnesota-based Zyga Technology, Inc. as of January 4, 2018.
Zyga Technology, a private company with approximately 30 employees and approximately $4 million in annual revenue, is known for SImmetry Sacroiliac Joint Fusion. Its primary product line is directed at conditions including sacroiliac joint disruptions and degenerative sacroiliitis.
"Acquiring Zyga Technology further advances our strategic transformation focused on reducing complexity, driving operational excellence and accelerating growth,” said Camille Farhat, president and CEO, in the news release. “We are increasing our focus on both internal development and external investment, and acquiring Zyga Technology’s innovative minimally invasive treatment both accentuates our robust spine portfolio and opens significant opportunities to accelerate growth."
Camille Farhat told OTW, “For RTI, reducing complexity means increasing our focus. We are increasing focus in areas where we are able to make the biggest impact and treat more patients with our products. Our efforts internally to drive operational excellence and reduce complexity, for example simplifying our portfolio, allowed us to take advantage of this unique opportunity with Zyga. As RTI repositions itself and accelerates growth, especially in the spine space, we are pleased to have Zyga be the first of many more growth opportunities to come, demonstrating our focus to the spine community.”
“Approximately 1.4 million SI injections are expected to be administered in 2017 in a total of 850,000 SI joint pain patients, 30% of which are referred to a spine surgeon for further evaluation and treatment. Too few patients are moving beyond SI injection to an SI procedure.”
“SImmetry Sacroiliac Joint Fusion system is a minimally invasive spine surgery procedure designed to help stabilize the SI joint. SImmetry is a commercially available and differentiated product—one of the few supported by clinical data—that continues to show fusion as early as 12 months and effective reductions in both pain and opioid use.”
“RTI is repositioning itself to be the company of next therapies for the spine community. We have an establish portfolio, with products such as nanOss, map3, and TETRAfuse 3D, in the spine space and are looking to accelerate our growth in this area, particularly by adding more burgeoning therapies early in the patient access journey, much like SImmetry, so we can better serve physicians and patients with innovative spine procedures and devices.”